AbCellera Biologics ABCL 深 沪
已收盘 08-01 16:00:00 美东时间
4.24
-0.230
-5.15%
华盛通- 最 高4.445
- 今 开4.23
- 成交量 665.44万股
- 最 低 4.185
- 昨 收 4.47
- 总市值 12.64亿
- 52周最高 5.82
- 市盈率 静 --
- 换手率 2.23%
- 52周最低 1.8906
- 委 比 -65.86%
- 总股本 2.98亿
- 历史最高 71.91
- 量 比 1.38
- 振 幅 5.82%
- 历史最低 1.8906
- 每 手 1
- 风险率 0.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on ...
07-21 22:16
美股大行评级 | 潜在涨幅199.47%！杰富瑞上调Cogent Biosciences目标价至28美元，维持"买入"评级
今日重点评级关注：杰富瑞：维持Cogent Biosciences"买入"评级，目标价从23美元升至28美元；Leerink Partners：维持Cogent Biosciences"跑赢大市"评级，目标价从16美元升至18美元
07-08 09:34
Leerink Partners Assumes AbCellera Biologics at Outperform, Announces Price Target of $5
Leerink Partners analyst Faisal Khurshid assumes AbCellera Biologics (NASDAQ:ABCL) with a Outperform rating and announces Price Target of $5.
07-07 20:39
Alector appoints Neil Berkley as interim CFO
Alector (NASDAQ:ALEC) announced on Friday that Marc Grasso, chief financial officer (CFO) of the company, will conclude his tenure effective June 20, 2025, to pursue other opportunities. Neil Berkley,...
06-14 04:15
美股牛股 | 量子之歌大涨33%！连续八个季度实现盈利；Insmed升超28%
量子之歌大涨33%！连续八个季度实现盈利；Insmed升超28%，TPIP在第二阶段研究中显示肺血管支撑位显著减少35%>>
06-11 19:19
Health Canada Grants No Objection Letter for AbCellera's ABCL575, Advancing Investigational OX40L Antibody For AD Treatment
ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitisAbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3
05-31 01:02
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
AbCellera Biologics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-17 01:39
AbCellera Biologics Receives Health Canada Approval for Trial
AbCellera Biologics ( ($ABCL) ) has issued an update. On May 14, 2025, AbCeller...
05-15 05:50
快讯 | AbCellera Biologics Inc - Abcl635的第一阶段试验预计将在2025年第三季度开始
Abcellera Biologics Inc - Phase 1 Trial for Abcl635 Expected to Start in Q3 2025
05-15 05:00
